TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03473977

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected every 4 weeks (total of 3 injections) as a comparator to Benralizumab in subjects with active Eosinophilic Gastritis.
Study: NCT00528788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxercalciferol
Study: NCT01712776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant (Pain Ease)
Description: Topical stream 4-10 seconds duration to skin.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nature's Tears Sterile Water
Description: Topical stream 4-10 seconds duration to skin
Study: NCT03705260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care from Primary Care Physician and dietitian.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care from Primary Care Physician and dietitian.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care from Primary Care Physician and dietitian.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Intervention
Description: The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Screening for Risk
Description: Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.
Study: NCT03460470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: PDE5 Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo for Sildenafil
Study: NCT03114098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gene abnormalities
Description: A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
Study: NCT02533661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family-centered intervention program
Description: This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
Study: NCT02643381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency Endotracheal Intubation
Description: Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emergency Endotracheal Intubation
Description: Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Ventilation
Description: Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
Study: NCT03205332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concreteness Training
Study: NCT03192111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: HDAC (histone deacetylase) inhibitor
Study: NCT00607919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, daily, for 16 weeks
Study: NCT01989871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjusted individual feeding
Description: Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
Study: NCT02583516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib and cobimetinib
Description: Comparison between different treatment regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib and cobimetinib
Description: Comparison between different treatment regimens
Study: NCT04128618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyMedica e-vive NMES
Description: Neuromuscular Electrical Stimulation (NMES) therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CyMedica e-vive NMES
Description: Neuromuscular Electrical Stimulation (NMES) therapy
Study: NCT03536923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leva Incontinence System For Pelvic Floor Muscle strengthening
Description: The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
Study: NCT04088565

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Paired-Associative Stimulation (PAS)
Description: Simultaneous activation of connections in motor cortex via stimulation to the nerves and brain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paired-Associative Stimulation (PAS)
Description: Simultaneous activation of connections in motor cortex via stimulation to the nerves and brain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Description: Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sub-threshold stimulation that does not activate neural structures.
Study: NCT02539914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality based upper-limb motor and cognitive task

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard upper-limb motor and cognitive rehabilitation tasks
Study: NCT02795611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-centered occupational therapy
Description: Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: regular occupational therapy
Description: regular occupational therapy
Study: NCT01911650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound Imaging
Description: A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaires
Description: This questionnaire is a self-report of pain and function associated with the Achilles tendon.

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaires
Description: This questionnaire is a self-report of pain and function associated with the Achilles tendon.
Study: NCT03671421

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction - graft choice
Description: Use of 3 different ipsilateral autograft options

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction - graft choice
Description: Use of 3 different ipsilateral autograft options

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction - graft choice
Description: Use of 3 different ipsilateral autograft options
Study: NCT02701959

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Nitrate Lettuce
Description: The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~530 mg nitrate derived).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low Nitrate Lettuce
Description: The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (\~3 mg nitrate derived).
Study: NCT00255918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethoxybenzylidene anabaseine (DMXB-A)
Description: DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
Study: NCT02795611

Intervention type: OTHER
Group type: OTHER
Intervention: intervention done outside our hospital
Description: intervention done outside our hospital
Study: NCT01527110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) zanamivir
Description: Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
Study: NCT00509652

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm 1: Erythrocyte apheresis
Description: Erythrocyte apheresis
Study: NCT00255918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethoxybenzylidene anabaseine (DMXB-A)
Description: DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dimethoxybenzylidene anabaseine (DMXB-A)
Description: DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
Study: NCT00509652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Whole blood phlebotomy
Description: Traditional whole blood phlebotomy
Study: NCT03940014

Intervention type: OTHER
Intervention: Data collection from standard follow up
Description: Annual clinical consultation with an Hereditary Haemorrhagic Telangiectasia (HHT) specialist and/or pneumologist and organ specialists when necessary (such as hepatologists, cardiologists and neurologists).~Explorations (contrast echography, chest Computed Tomography and treatments performed according to international guidelines.~TransCatheter Embolotherapy for each treatable Pulmonary Arteriovenous Malformations (PAVMs) and follow-up every 3 years.~Chest Computed Tomography (CT) every 6-12 months.
Study: NCT02401113

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UA group
Description: Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
Study: NCT01785927

Intervention type: OTHER
Group type: OTHER
Intervention: ABCD
Description: Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).

Intervention type: OTHER
Group type: OTHER
Intervention: ABCD
Description: Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).

Intervention type: OTHER
Group type: OTHER
Intervention: ABCD
Description: Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
Study: NCT02401113

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: UA group
Description: Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
Study: NCT03999385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion (MSC)
Description: The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindful Self-Compassion (MSC)
Description: The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.
Study: NCT00805012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel+CDDP
Description: docetaxel+CDDP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel+S-1
Description: docetaxel+S-1
Study: NCT01570309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: Oral capsule, 50,000 units, once a week, 12 weeks
Study: NCT00255918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dosed to match active medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dosed to match active medication
Study: NCT01570309

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Oral capsule, once a week, 12 weeks
Study: NCT01425645

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FDD program
Description: FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
Study: NCT00615212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK376501
Description: GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK376501
Description: GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK376501
Description: GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK376501
Description: GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen
Description: Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
Study: NCT04213183

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatobiliary Disorders
Description: The training dataset was used to train the deep learning model, which was validated and tested by the other two datasets.
Study: NCT00255918

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dosed to match active medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethoxybenzylidene anabaseine (DMXB-A)
Description: DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethoxybenzylidene anabaseine (DMXB-A)
Description: DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dimethoxybenzylidene anabaseine (DMXB-A)
Description: DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
Study: NCT02855021

Intervention type: OTHER
Group type: OTHER
Intervention: Explorations
Description: Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.~Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.~These tests do not require discontinuation of Parkinson's disease treatment.
Study: NCT03353363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of bupivacaine 0.5% plain will be infiltrated into the wound by the obstetrician team in a standardized fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of one liposomal bupivacaine will be infiltrated into the wound by the obstetrician team in a standardized fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
Study: NCT02415244

Intervention type: PROCEDURE
Intervention: TEE
Description: Spinal cord segments will be imaged using the TEE

Intervention type: PROCEDURE
Intervention: TEE
Description: Spinal cord segments will be imaged using the TEE
Study: NCT01720875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat Velcade Dexamethasone
Study: NCT03773900

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kiotransine (chitin-glucan from aspergillus niger)
Description: The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water.
Study: NCT02079909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-817MA-H
Description: 224 mg or 448 mg T-817 MA once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-817MA-L
Description: 224 mg T-817 MA once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02329977

Intervention type: OTHER
Intervention: standard barium meal examination
Description: All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.

Intervention type: OTHER
Intervention: standard barium meal examination
Description: All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.